EQUASENS: 2022 Net Profit: +18.35% to €48.70m
March 24 2023 - 1:00PM
EQUASENS: 2022 Net Profit: +18.35% to €48.70m
Villers-lès-Nancy, 24 March 2023 - 6:00 p.m.
(CET)
PRESS RELEASE
2022 Net Profit: +18.35% to €48.70m
- Revenue:
+10.88% to €214.07m.
- Strong growth
driven by the French Digital Healthcare investment programme (Ségur
du Numérique en Santé) and a continuing focus on its
deployment.
- A significant
increase in the contribution of "non-pharmacy" growth drivers to
Equasens Group’s 2022 revenue.
- A high
level of profitability and a strong balance sheet and strong cash
position giving the Group considerable flexibility
in terms of debt capacity.
- Current Operating
Income: +12.57% to €56.79m.
- Net Profit: +18.35%
to €48.70m.
- Basic Earnings per
Share: +18.52% to €3.09.
- Cash Flow: +17.07%
to €62.05m.
- Dividend
proposal for FY 2022: € 1.15 per share
(+9.52%).
-
2023 Outlook:
the Group's financial strength (no net debt and a positive net cash
position of €56.26m) ensures it the resources to pursue its goals
for expansion in Europe and develop in other areas of the
healthcare sector.
In €m |
2021 |
2022 |
Change2022/2021 |
Revenue |
193.07 |
214.07 |
10.88% |
Current Operating Income |
50.45 |
56.79 |
12.57% |
Net Profit |
41.15* |
48.70** |
18.35% |
Net Profit attributable to the Group |
39.12 |
46.38 |
18.56% |
Basic earnings per share (in €) |
2.60 |
3.09 |
18.52% |
* Of which IP BOX 2021: €2.94m** Of which net IP BOX 2022:
€7.74m
Under the chairmanship of Thierry CHAPUSOT, the
Board of Directors met on 24 March 2023, in the presence of the
Statutory Auditors, to examine and approve the accounts for fiscal
2022. The audit procedures for the consolidated accounts have been
performed. The auditors' report will be issued after the management
report has been reviewed and the procedures for filing the annual
financial report have been completed.
- ANNUAL OPERATING HIGHLIGHTS
- Pharmagest
Division
- id. was the first Segur-certified
pharmacy management suite.
- ASCA is continuing its
transformation from an expert in electronic labelling to a
specialist in pharmacy equipment.
- Axigate Link
Division
- All of the Division's business
lines are growing in their respective markets, boosted notably by
the Ségur certification of five of the Division's software products
(nursing homes, multidisciplinary group practices, hospital-at-home
programmes, in-home nursing, hospital EMR).
- Significant resources have been
deployed for the roll-out in Q3 and Q4 2022 and to cover 100% of
customers.
- pandaLAB Pro achieved significant
growth in revenue (+36% to €1.14m), in response to the dual ISO
27001 and HDS certification of the PANDALAB software
developer.
- Medical Solutions
Division
- 2022 represented the first
full-year of PROKOV Editions' integration.
- 2022 also saw the development,
certification by the ANS and deployment of the Ségur programme and
the transfer of MédiStory 3 customers to MédiStory 4.
- Lastly, a recurring business model
was introduced for all MédiStory 4 customers during the
period.
- e-Connect
Division
- 2022 was impacted by supply chain
tensions and disruptions and skyrocketing prices for components. To
limit its effects, the Division decided to accelerate its strategy
of increasing the diversification of its manufacturing
subcontracting.
- The NOVIACare solution integrated
the Boulanger Marketplace and the qualifying European partners
validated the first orders of boxes for delivery in H1 2023.
- Fintech Division
- 2022 was marked by the decision to
diversify its range of business providers as well as by significant
rate increases.
- In Europe
- PHARMAGEST ITALIA continued to grow
with nearly 150 new pharmacies now equipped and the roll-out of its
compliance offer.
- MALTA BELGIUM is equipping the
first Care Homes sites with TITANLINK.
- Buy-out of minority interests:
PHARMAGEST ITALIA, CAREMEDS, I-MEDS and MULTIMEDS.
- CONSOLIDATED FINANCIAL HIGHLIGHTS
Group Equasens reported annual revenue of
€214.07m up 10.88% from 31 December 2021. Like-for-like (incl.
PROKOV Editions in Q4), FY 2022 revenue rose 8.82% to
€210.09m. The Group confirms the efficiency of its strategy of
promoting interoperability between healthcare professionals and
establishments, with the priorities of structuring the healthcare
offer, improving coordination between healthcare professionals and
exchanging patient data.
Current Operating Income for the Group
totalled €56.79m, up 12.57% from 2021. By
Division, Current Operating Income broke down as follows:
- Pharmagest
Division: €36.16m, i.e.
63.67% of the Group total. While the largest contribution, its
impact was mitigated by the performance of the other Divisions and
the increased share of hardware in the revenue mix.
- Axigate
Link Division (Health and Social Care Facilities):
€11.70m, i.e. 20.60% of the Group total. This
included a significant increase in revenue from the Ségur
programme.
- e-Connect
Division: €6.21m, i.e. 10.93% of the
Group total. Slower growth in response to pressure on the supply
chain for components.
- Medical
Solutions: €3.08m, i.e. 5.42% of the
Group total. Better-than-expected results with the deployment of
MédiStory 4 and a new business model focused on recurring
revenue.
-
Fintech:
-€0.34m, i.e. -0.60% of the Group
total. An activity adversely impacted by market turmoil and
unfavourable financing conditions
Net Profit rose by 18.35% to €48.70m,
including
€7.74m
from net IP BOX.
Basic earnings per share
rose 18.52% to
€3.09 (€2.60 in 2021).
With respect to its balance sheet, the
Group continues to benefit from its strong investment
capacity with a gross cash position of €119.20m at 31
December 2022. In addition, at 31/12/2022, the company held 142,428
own shares valued at €10.02m.
Shareholders' equity stood at €196.80m
at 31 December 2022 compared to €165.24m at the end of
2021. The Group confirms its growth potential supported by
its strong cash position, with 17.07%
growth in cash flow to €62.05m and a
reduction in financial liabilities.
For more than 10 years, Equasens Group has been
creating shareholder value and maintained its efforts to distribute
dividends. The Group will propose to the Annual General Meeting on
29 June 2023 a gross dividend per share of
€1.15
(+9.52%).
2022 confirmed the efficiency of the Equasens
Group's growth strategy (organic and external) and the
qualification of its software products for the Ségur programme
attests to its know-how and technological expertise.
The Group also confirms its financial solidity
(no net debt and a positive net cash position of €56.26m) ensuring
it the resources to achieve its goals for expansion in Europe and
develop in other areas of the healthcare
sector.
Upcoming events
- End of April 2023: Release of the
2022 Universal Registration Document
- 11 May 2023: Publication of
Q1 2023 revenue
- 29 June 2023: Annual General
Meeting
- 3 August 2023: Publication of
H1 2023 revenue.
About Group Equasens
With more than 1,200 employees fulfilling a
vital role as “Citizens in the Service of Health and Well-Being”,
Equasens Group is today a key player in the European healthcare
sector, providing software solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
Hospital-at-Home structures, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in in France, Germany, Great
Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group
today brings together healthcare professionals within a unique
ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Included in the Euronext Tech Leaders segment
and the European Rising Tech label Indexes: MSCI GLOBAL SMALL CAP -
GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR0012882389 - Ticker
Code: EQS
For all the latest news on Equasens Group go to
www.equasens.com
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer:
Frédérique SCHMIDTTel. +33 (0)3 83 15 90 67 -
frederique.schmidt@equasens.com
Media
Relations:FIN’EXTENSO – Isabelle APRILE
Tel. +33 (0)6 17
38 61 78 - i.aprile@finextenso.fr
- EQUASENS_PRESSRELEASE_20230324_2022 NET PROFIT_en_US
Equasens (EU:EQS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Equasens (EU:EQS)
Historical Stock Chart
From Jul 2023 to Jul 2024